42004 Scalp, Eyebrow, and Eyelash Hair Regrowth with Continued Ritlecitinib Treatment among Patients with Alopecia Areata Without Target Efficacy Response at Week 24: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Journal of the American Academy of Dermatology(2023)
Abstract
Background: This post hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) assessed response to ritlecitinib, an oral JAK3/TEC inhibitor, between Weeks 28-48 among patients with alopecia areata (AA) who did not meet target efficacy response criteria at Week 24.
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined